

Pubblicazioni

2014

Bauer S., Rutkowski P., Hohenberger P., Miceli R., Fumagalli E., Siedlecki J.A., Nguyen B.P., Kerst M., Fiore M., Nyckowski P., Hoicznyk M., Cats A., Casali P.G., Treckmann J., van Coevorden F., Gronchi A.: Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - Analysis of prognostic factors (EORTC-STBSG collaborative study). *Eur J Surg Oncol* 2014; 40: 412-419 [IF 2.892]

Bellmunt J., Orsola A., Leow J.J., Wiegel T., De Santis M., Horwich A., Casali P.G., Licitra L., Colombo N., Ladetto M.: Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii40-iii48 [IF 6.578]

Blay J.Y., Casali P.G., Nieto A., Tanovic A., Le Cesne A.: Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. *Future Oncol* 2014; 10: 59-68 [IF 2.611]

Bozzi F., Manenti G., Conca E., Stacchiotti S., Messina A., Dagrada G., Gronchi A., Panizza P., Pierotti M.A., Tamborini E., Pilotti S.: Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. *Neuro-Oncology* 2014; 16: 72-80 [IF 5.286]

Casali P.G.: Risks of the new EU Data protection regulation: An ESMO position paper endorsed by the European oncology community. *Ann Oncol* 2014; 25: 1458-1461 [IF 6.578]

Casali P.G.: Successes and limitations of targeted cancer therapy in gastrointestinal stromal tumors. *Prog Tumor Res* 2014; 41: 51-61

Casali P.G.: Rare cancers: Work in progress in Europe. *Ann Oncol* 2014; 25: 914-914

Cherny N.I., ESMO Guidelines Working Group, Casali P.G., Licitra L.: ESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. *Ann Oncol* 2014; 25 Suppl 3: iii143-iii152 [IF 6.578]

Ciardiello F., Arnold D., Casali P.G., Cervantes A., Douillard J.-Y., Eggermont A., Eniu A., McGregor K., Peters S., Piccart M., Popescu R., van Cutsem E., Zielinski C., Stahel R.: Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: A position paper by the European Society for Medical Oncology (ESMO). *Ann Oncol* 2014; 25: 1673-1678 [IF 6.578]

Coleman R., Body J.J., Apro M., Hadji P., Herrstedt J., Casali P.G., Licitra L.: Bone health in cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol* 2014; 25 Suppl 3: iii124-iii137 [IF 6.578]

De Cecco L.D., Negri T., Brich S., Mauro V., Bozzi F., Dagrada G., Disciglio V., Sanfilippo R., Gronchi A., Maurizio D'Incalci, Casali P.G., Canevari S., Pierotti M.A., Pilotti S.: Identification of a gene expression driven progression pathway in Myxoid liposarcoma. *Oncotarget* 2014; 5: 5965-5977 [IF 6.627]

Di Giandomenico S., Frapolli R., Bello E., Ubaldi S., Licandro S.A., Marchini S., Beltrame L., Brich S., Mauro V., Tamborini E., Pilotti S., Casali P.G., Grosso F., Sanfilippo R., Gronchi A., Mantovani R., Gatta R., Galmarini C.M., Sousa-Faro J.M., D'Incalci M.: Mode of action of trabectedin in myxoid liposarcomas. *Oncogene* 2014; 33: 5201-5210 [IF 8.559]

Dreyling M., Geisler C., Hermine O., Kluin-Nelemans H.C., Le Gouill S., Rule S., Shpilberg O., Walewski J., Ladetto M., Casali P.G., Licitra L., Colombo N., Ladetto M.: Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii83-iii92 [IF 6.578]

Dreyling M., Ghilmini M., Marcus R., Salles G., Vitolo U., Ladetto M., Casali P.G., Licitra L.: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii76-iii82 [IF 6.578]

Eichenauer D.A., Engert A., Andre M., Federico M., Illidge T., Hutchings M., Ladetto M., Casali P.G., Licitra L.: Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii70-iii75 [IF 6.578]

Escudier B., Porta C., Schmidinger M., Algaba F., Patard J.J., Khoo V., Eisen T., Horwich A., Casali P.G., Licitra L.: Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii49-iii56 [IF 6.578]

Fenaux P., Haase D., Sanz G.F., Santini V., Buske C., Casali P.G., Licitra L.: Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii57-iii69 [IF 6.578]

Fiore M., Coppola S., Cannell A.J., Colombo C., Bertagnolli M.M., George S., Le Cesne A., Gladdy R.A., Casali P.G., Swallow C.J., Gronchi A., Bonvalot S., Raut C.P.: Desmoid-type fibromatosis and pregnancy: A multi-institutional analysis of recurrence and obstetric risk. *Ann Surg* 2014; 259: 973-978 [IF 7.188]

Granata R., Bossi P., Bertulli R., Saita L.: Rapid-onset opioids for the treatment of breakthrough cancer pain: Two cases of drug abuse. *Pain Med* 2014; 15: 758-761 [IF2.243]

Gronchi A., Colombo C., Le Pıchoux C., Dei Tos A.P., Le Cesne A., Marrari A., Penel N., Grignani G., Blay J.Y., Casali P.G., Stoeckle E., Gherlinzoni F., Meeus P., Mussi C., Gouin F., Duffaud F., Fiore M., Bonvalot S.: Sporadic desmoid-type fibromatosis: A stepwise approach to a non-metastasising neoplasm-A position paper from the Italian and the French Sarcoma Group. *Ann Oncol* 2014; 25: 578-583 [IF 6.578]

Gronchi A., De Paoli A., Dani C., Merlo D.F., Quagliuolo V., Grignani G., Bertola G., Navarria P., Sangalli C., Buonadonna A., De Sanctis R., Sanfilippo R., Dei Tos A.P., Stacchiotti S., Giorello L., Fiore M., Bruzzi P., Casali P.G.: Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group. *Eur J Cancer* 2014; 50: 784-792 [IF 4.819]

Martin-Broto J., Gutierrez A.M., Ramos R.F., Lopez-Guerrero J.A., Ferrari S., Stacchiotti S., Picci P., Calabuig S., Collini P., Gambarotti M., Bague S., Dei Tos A.P., Palassini E., Luna P., Cruz J., Cubedo R., Martinez-Trufero J., Poveda A., Casali P.G., Fernandez-Serra A., Lopez-Pousa A., Gronchi A.: MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study. *Mol Cancer Ther* 2014; 13: 249-259 [IF 6.107]

Milione M., Gasparini P., Sozzi G., Mazzaferro V., Ferrari A., Casali P.G., Perrone F., Tamborini E., Pellegrinelli A., Gherardi G., Arrigoni G., Collini P., Testi A., De Paoli E., Aiello A., Pilotti S., Pelosi G.: Ewing sarcoma of the small bowel: A study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation. *Histopathology* 2014; 64: 1014-1026 [IF 3.301]

Morosi C., Stacchiotti S., Marchianr A., Bianchi A., Radaelli S., Sanfilippo R., Colombo C., Richardson C., Collini P., Barisella M., Casali P.G., Gronchi A., Fiore M.: Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. *EJSO-EUR J SURG ONC* 2014; 40: 1662-1670 [IF 2.892]

Popescu R.A., Schafer R., Califano R., Eckert R., Coleman R., Douillard J.Y., Cervantes A., Casali P.G., Sessa C., Van Cutsem E., de Vries E., Pavlidis N., Fumasoli K., WormannB., Samonigg H., Cascinu S., Cruz Hernandez J.J., Howard A.J., Ciardiello F., Stahel R.A., Piccart M.: The current and future role of the medical oncologist in the professional care for cancer patients: A position paper by the European Society for Medical Oncology (ESMO). *Ann Oncol* 2014; 25: 9-15 [IF 6.578]

Radaelli S., Stacchiotti S., Casali P.G., Gronchi A.: Emerging therapies for adult soft tissue sarcoma. *Expert Rev Anticancer Ther* 2014; 14: 689-704 [IF 2.279]

Reck M., Popat S., Reinmuth N., De Ruyscher D., Kerr K.M., Peters S., Casali P.G., Licitra L., Colombo N., Ladetto M.: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii27-iii39 [IF 6.578]

Schrijvers D., Cherny N.I., Casali P.G., Licitra L., Colombo N., Ladetto M.: ESMO Clinical Practice Guidelines on palliative care: advanced care planning. *Ann Oncol* 2014; 25 Suppl 3: iii138-iii142 [IF 6.578]

Stacchiotti S., Pantaleo M.A., Astolfi A., Dagrada G.P., Negri T., Dei Tos A.P., Indio V., Morosi C., Gronchi A., Colombo C., Conca E., Toffolatti L., Tazzari M., Crippa F., Maestro R., Pilotti S., Casali P.G.: Activity of sunitinib in extraskeletal myxoid chondrosarcoma. *Eur J Cancer* 2014; 50: 1657-1664 [IF 4.819]

Stacchiotti S., Tortoreto M., Baldi G.G., Grignani G., Toss A., Badalamenti G., Cominetti D., Morosi C., Dei Tos A.P., Festinese F., Fumagalli E., Provenzano S., Gronchi A., Pennacchioli E., Negri T., Dagrada G.P., Spagnuolo R.D., Pilotti S., Casali P.G., Zaffaroni N.: Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. *Eur J Cancer* 2014; 50: 3021-3028 [IF 4.819]

Stupp R., Brada M., van den Bent M.J., Tonn J.C., Pentheroudakis G., Casali P.G., Licitra L., Colombo N., Ladetto M.: High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii93-ii101 [IF 6.578]

Tazzari M., Negri T., Rini F., Vergani B., Huber V., Villa A., Dagrada P., Colombo C., Fiore M., Gronchi A., Stacchiotti S., Casali P.G., Pilotti S., Rivoltini L., Castelli C.: Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer* 2014; 111: 1350-1362 [IF 4.817]

The ESMO/European Sarcoma Network Working Group, Casali P.G., Ferrari A., Gronchi A., Morosi C., Stacchiotti S., Trama A.: Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii21-iii26 [IF 6.578]

The ESMO/European Sarcoma Network Working Group, Ferrari A., Gronchi A., Morosi C., Stacchiotti S., Trama A., Casali P.G., Licitra L.: Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii102-iii112 [IF 6.578]

The ESMO/European Sarcoma Network Working Group, Ferrari A., Gronchi A., Morosi C., Stacchiotti S., Trama A., Radaelli S., Tamborini E., Casali P.G., Licitra L.: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii113-iii123 [IF 6.578]

Van Cutsem E., Cervantes A., Nordlinger B., Arnold D., Casali P.G., Licitra L., Colombo N., Ladetto M.: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2014; 25 Suppl 3: iii1-iii9 [IF 6.578]

2013

Angelini S., Pantaleo M.A., Ravegnini G., Zenesini C., Cavrini G., Nannini M., Fumagalli E., Palassini E., Saponara M., Di Battista M., Casali P.G., Hrelia P., Cantelli-Forti G., Biasco G.: Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. *Pharmacol Res.* 2013 Feb;68(1):1-6. doi: 10.1016/j.phrs.2012.10.015. Epub 2012 Nov 2

Baldi G.G., Stacchiotti S., Mauro V., Dei Tos A.P., Gronchi A., Pastorino U., Duranti .L, Provenzano S., Marrari A., Libertini M., Pilotti S., Casali P.G.: Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. *Clin Sarcoma Res.* 2013 Apr 3;3(1):4. [Epub ahead of print]

Baratti D., Kusamura S., Cabras A.D., Bertulli R., Hutanu I., Deraco M.: Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). *Eur J Cancer.* 2013 Oct;49(15):3140-8. doi: 10.1016/j.ejca.2013.05.027. Epub 2013 Jul 4.

Berger M., Fagioli F., Abate M., Riccardi R., Prete A., Cozza R., Bertulli R., Podda M., Ferrari S., Luksch R.: Unusual sites of Ewing sarcoma (ES): a retrospective multicenter 30-year experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP) and Italian Sarcoma Group (ISG). *Eur J Cancer.* 2013 Nov;49(17):3658-65. doi: 10.1016/j.ejca.2013.06.045. Epub 2013 Jul 24.

Bozzi F., Manenti G., Conca E., Stacchiotti S., Messina A., Dagrada G., Gronchi A., Panizza P., Pierotti M.A., Tamborini E., Pilotti S.: Development of transplantable human chordoma xenograft

for preclinical assessment of novel therapeutic strategies. *Neuro Oncol.* 2013 Dec 16. [Epub ahead of print]

Bozzi F., Conca E., Laurini E., Posocco P., Lo Sardo A., Jocollè G., Sanfilippo R., Gronchi A., Perrone F., Tamborini E., Pelosi G., Pierotti M.A., Maestro R., Pricl S., Pilotti S.: In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. *Lab Invest.* 2013 Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep

Casali P.G.: Improving methodology to go beyond histology in rare cancers. Comment on: Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. *Lancet Oncol.* 2013 Apr;14(4):276-7. doi: 10.1016/S1470-2045(13)70089-5. Epub 2013 Mar 8.

Castelli C., Tazzari M., Negri T., Vergani B., Rivoltini L., Stacchiotti S., Pilotti S.: Structured myeloid cells and anti-angiogenic therapy in alveolar soft part sarcoma. *J Transl Med.* 2013 Sep 27;11:237. doi: 10.1186/1479-5876-11-237.

Conca E., Miranda C., Dal Col V., Fumagalli E., Pelosi G., Mazzoni M., Fermeiglia M., Laurini E., Pierotti M.A., Pilotti S., Greco A., Pricl S., Tamborini E.: Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib. *Mol Oncol.* 2013 Aug;7(4):756-62. doi: 10.1016/j.molonc.2013.02.019. Epub 2013 Mar 21.

Demetri G.D., Reichardt P., Kang Y.K., Blay J.Y., Rutkowski P., Gelderblom H., Hohenberger P., Leahy M., von Mehren M., Joensuu H., Badalamenti G., Blackstein M., Le Cesne A., Schöffski P., Maki R.G., Bauer S., Nguyen B.B., Xu J., Nishida T., Chung J., Kappeler C., Kuss I., Laurent D., Casali P.G.; GRID study investigators: Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet.* 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22.

Deraco M., Baratti D., Hutanu I., Bertulli R., Kusamura S.: The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. *Ann Surg Oncol* 2013; 20: 1093-1100

Di Giandomenico S., Frapolli R., Bello E., Uboldi S., Licandro S.A., Marchini S., Beltrame L., Brich S., Mauro V., Tamborini E., Pilotti S., Casali P.G., Grosso F., Sanfilippo R., Gronchi A., Mantovani R., Gatta R., Galmarini C.M., Sousa-Faro J.M., D'Incalci M.: Model of action of trabectedin in myxoid liposarcomas. *Oncogene.* 2013 Nov 11. doi: 10.1038/onc.2013.462. [Epub ahead of print]

Ditto A., Martinelli .F, Carcangiu M., Solima E., de Carrillo K.J., Sanfilippo R., Haeusler E., Raspagliesi F.: Embryonal rhabdomyosarcoma of the uterine cervix in adults: a case report and literature review. *J Low Genit Tract Dis.* 2013 Oct;17(4):e12-7. doi: 10.1097/LGT.0b013e31827a8b8c.

Duranti L., Gronchi A., Stacchiotti S., Fiore M., Casali P.G., Collini P., Pelosi G., Galeone C., Pastorino U.: Localised thoracic sarcomas: outcome improvement over time at a single institution. *Eur J Cancer.* 2013 Aug;49(12):2689-97. doi: 10.1016/j.ejca.2013.04.007. Epub 2013 May 14.

Ferrari A., Veneroni L., Clerici C.A., Spreafico F., Terenziani M., Luksch R., Casanova M., Meazza C., Polastri D., Gandola L., Massimino M., Fumagalli E.: Adolescents suffering from cancer: "Youth Project" of the National Cancer Institute of Milan Recenti. *Progressi Medicina* 2013; 104: 10-16

Fiore M., Coppola S., Cannell A.J., Colombo C., Bertagnolli M.M., George S., Le Cesne A., Gladdy R.A., Casali P.G., Swallow C.J., Gronchi A., Bonvalot S., Raut C.P.: Desmoid-Type Fibromatosis and Pregnancy: A Multi-institutional Analysis of Recurrence and Obstetric Risk. *Ann Surg.* 2013 Oct 10. [Epub ahead of print]

Germano G., Frapolli R., Belgiovine C., Anselmo A., Pesce S., Liguori M., Erba E., Uboldi S., Zucchetti M., Pasqualini F., Nebuloni M., van Rooijen N., Mortarini R., Beltrame L., Marchini S., Fuso Nerini I., Sanfilippo R., Casali P.G., Pilotti S., Galmarini C.M., Anichini A., Mantovani A., D'Incalci M., Allavena P.: Role of macrophage targeting in the antitumor activity of trabectedin. *Cancer Cell.* 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.

Gronchi A., Casali P.G.: Adjuvant therapy for high-risk soft tissue sarcoma in the adult. *Curr Treat Options Oncol.* 2013 Sep;14(3):415-24. doi: 10.1007/s11864-013-0243-7.

Gronchi A., De Paoli A., Dani C., Merlo D.F., Quagliuolo V., Grignani G., Bertola G., Navarria P., Sangalli C., Buonadonna A., De Sanctis R., Sanfilippo R., Dei Tos A.P., Stacchiotti S., Giorello L., Fiore M., Bruzzi P., Casali P.G.: Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group. *Eur J Cancer.* 2013 Dec 5. pii: S0959-8049(13)01017-4. doi: 10.1016/j.ejca.2013.11.021. [Epub ahead of print]

Gronchi A., Verderio P., De Paoli A., Ferraro A., Tendero O., Majò J., Martin J., Comandone A., Grignani G., Pizzamiglio S., Quagliuolo V., Picci P., Frustaci S., Dei Tos A.P., Palassini E., Stacchiotti S., Ferrari S., Fiore M., Casali P.G.: Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. *Ann Oncol.* 2013 Mar;24(3):817-23. doi: 10.1093/annonc/mds501. Epub 2012 Oct 30.

Gronchi A., Colombo C., Le Péchoux C., Dei Tos A.P., Le Cesne A., Marrari A., Penel N., Grignani G., Blay J.Y., Casali P.G., Stoeckle E., Gherlinzoni F., Meeus P., Mussi C., Gouin F., Duffaud F., Fiore M., Bonvalot S.; on behalf of ISG and FSG.: Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. *Ann Oncol.* 2013 Dec 9. [Epub ahead of print]

Mallone S., De Angelis R., van der Zwan J.M., Trama A., Siesling S., Gatta G., Capocaccia R.; RARECARE W.G.: Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. *Cancer Epidemiol.* 2013 Dec;37(6):850-6. doi: 10.1016/j.canep.2013.08.001. Epub 2013 Sep 16.

Mattavelli D., Miceli R., Radaelli S., Mattavelli F., Cantù G., Barisella M., Quattrone P., Stacchiotti S., Sangalli C., Casali P.G., Gronchi A., Fiore M.: Head and neck soft tissue sarcomas: prognostic

factors and outcome in a series of patients treated at a single institution. *Ann Oncol*. 2013 Aug;24(8):2181-9. doi: 10.1093/annonc/mdt126. Epub 2013 Apr 5.

Penel N., Demetri G.D., Blay J.Y., Cousin S., Maki R.G., Chawla S.P., Judson I., von Mehren M., Schöffski P., Verweij J., Casali P.G., Rodenhuis S., Schütte H.J., Cassar A., Gomez J., Nieto A., Zintl P., Pontes M.J., Le Cesne A.: Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. *Ann Oncol* 2013; 24: 537-542

Rutkowski P., Gronchi A., Hohenberger P., Bonvalot S., Schöffski P., Bauer S., Fumagalli E., Nyckowski P., Nguyen B.P., Kerst J.M., Fiore M., Bylina E., Hoiczuk M., Cats A, Casali P.G., Le Cesne A., Treckmann J., Stoeckle E., de Wilt J.H., Sleijfer S., Tielen R., van der Graaf W., Verhoef C., van Coevorden: Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. *Ann Surg Oncol*. 2013 Sep;20(9):2937-43. doi: 10.1245/s10434-013-3013-7. Epub 2013 Jun 13.

Sanfilippo R., Dei Tos A.P., Casali P.G.: Myxoid liposarcoma and the mammalian target of rapamycin pathway. *Curr Opin Oncol*. 2013 Jul;25(4):379-83. doi: 10.1097/CCO.0b013e32836227ac.

Sanfilippo R., Casali P.G.: The intriguing patterns of tumor response to trabectedin. *Expert Rev Anticancer Ther*. 2013 Jun;13(6 Suppl 1):21-4. doi: 10.1586/era.13.51.

Stacchiotti S., Dagrada G.P., Sanfilippo R., Negri T., Vittimberga I., Ferrari S., Grosso F., Apice G., Tricoli M., Colombo C., Gronchi A., Dei Tos A.P., Pilotti S., Casali P.G.: Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. *Clin Sarcoma Res*. 2013 Dec 18;3(1):16. doi: 10.1186/2045-3329-3-16.

Stacchiotti S., Tortoreto M., Bozzi F., Tamborini E., Morosi C., Messina A., Libertini M., Palassini E., Cominetti D., Negri T., Gronchi A., Pilotti S., Zaffaroni N., Casali P.G.: Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-a-vis temozolomide and antiangiogenics. *Clin Cancer Res*. 2013 Sep 15;19(18):5192-201. doi: 10.1158/1078-0432.CCR-13-0776. Epub 2013 Jul 25.

Stacchiotti S., Tamborini E., Lo Vullo S., Bozzi F., Messina A., Morosi C., Casale A., Crippa F., Conca E., Negri T., Palassini E., Marrari A., Palmerini E., Mariani L., Gronchi A., Pilotti S., Casali P.G.: Phase II study on lapatinib in advanced EGFR-positive chordoma. *Ann Oncol*. 2013 Jul;24(7):1931-6. doi: 10.1093/annonc/mdt117. Epub 2013 Apr 4.

Stacchiotti S., Libertini M., Negri T., Palassini E., Gronchi A., Fatigoni S., Poletti P., Vincenzi B., Dei Tos A.P., Mariani L., Pilotti S., Casali P.G.: Response to chemotherapy of solitary fibrous tumour: a retrospective study. *Eur J Cancer*. 2013 Jul;49(10):2376-83. doi: 10.1016/j.ejca.2013.03.017. Epub 2013 Apr 6.

Stacchiotti S., Crippa F., Messina A., Pilotti S., Gronchi A., Blay J.Y., Casali P.G.: Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. *Clin Sarcoma Res*. 2013 May 13;3(1):8. doi: 10.1186/2045-3329-3-8.

Stacchiotti S., Marrari A., Dei Tos A.P., Casali P.G.: Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS. *Hematol Oncol Clin North Am.* 2013 Oct;27(5):1049-61. doi: 10.1016/j.hoc.2013.07.009.

Stiller C.A., Trama A., Serraino D., Rossi S., Navarro C., Chirlaque M.D., Casali P.G.; RARECARE Working Group.: Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. *Eur J Cancer.* 2013 Feb;49(3):684-95. doi: 10.1016/j.ejca.2012.09.011. Epub 2012 Oct 15.

Waks Z., Goldbraich E., Farkash A., Torresani M., Bertulli R., Restifo N., Locatelli P., Casali P., Carmeli B.: Analyzing the "CareGap": assessing gaps in adherence to clinical guidelines in adult soft tissue sarcoma. *Study Health Technol Inform.* 2013;186:46-50.

2012

Carmeli B., Casali P.G., Goldbraich A., Kent C., Licitra L., Locatelli P., Restifo N., Rinott R., Sini E., Torresani M., Waks Z.: Evicase: An Evidence-based Case Structuring Approach for Personalized Healthcare. *Stud Health Technol Inform* 2012; 180: 604-608 [IF 0]

Casali P.G., Fumagalli E., Gronchi A.: Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). *Curr Treat Options Oncol* 2012; 13: 277-284 [IF 2,684]

Casali P.G.: Histology- and non-histology-driven therapy for treatment of soft tissue sarcomas. *Ann Oncol* 2012; 23: Suppl 10 x: 167-169 [IF 6,425]

Cassier P.A., Fumagalli E., Rutkowski P., Schöffski P., Van Glabbeke M., Debiec- Rychter M., Emile J.F., Duffaud F., Martin-Broto J., Landi B., Adenis A., Bertucci F., Bompas E., Bouchè O., Leyvraz S., Judson I., Verweij J., Casali P.G., Blay J.Y., Hohenberger P., for the European Organisation for Research and Treatment of Cancer: Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era. *Clin Cancer Res* 2012; 18: 4458-4464 [IF 7,742]

Cassier P.A., Gelderblom H., Stacchiotti S., Thomas D., Maki R.G., Kroep J.R., van der Graaf W.T., Italiano A., Seddon B., Domont J., Bompas E., Wagner A.J., Blay J.Y.: Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. *Cancer* 2012; 118: 1649 - 1655 [IF 4,771]

Collini P., Negri T., Barisella M., Palassini E., Tarantino E., Pastorino U., Gronchi A., Stacchiotti S., Pilotti S.: High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors: A Clinicopathologic Study of 10 Cases. *Am J Surg Pathol* 2012; 36: 1202-1215 [IF 4,352]

Colombo C., Miceli R., Collini P., Radaelli S., Palassini E., Stacchiotti S., Fiore M., Mariani L., Casali P.G., Gronchi A.: Leiomyosarcoma and sarcoma with myogenic differentiation: Two different entities or 2 faces of the same disease? *Cancer* 2012; 118: 5349-5357 [IF 4,771]

Crocetti E., Trama A., Stiller C., Caldarella A., Soffietti R., Jaal J., Weber D.C., Ricardi U., Slowinski J., Brandes A., Contiero P., Casali P.G., Gatta G., Gronchi A., Licitra L., RARECARE working group: Epidemiology of glial and non-glial brain tumours in Europe.1 *Eur J Cancer* 2012; 48: 1532-1542 [IF 5,536]

Demetri G.D., Garrett C.R., Schoffski P., Shah M.H., Verweij J., Leyvraz S., Hurwitz H.I., Pousa A.L., Le Cesne A., Goldstein D., Paz-Ares L., Blay J.Y., McArthur G.A., Xu Q., Huang X., Harmon C.S., Tassell V., Cohen D.P., Casali P.G.: Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure. *Clin Cancer Res* 2012; 18: 3170-3179 [IF 7,742]

Faivre J., Trama A., De Angelis R., Elferink M., Siesling S., Audisio R., Bosset J.F., Cervantes A., Lepage C., Contiero P., Casali P.G., Gatta G., Gronchi A., Licitra L., The RARECARE Working Group: Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. *Eur J Cancer* 2012; 48: 1417-1424 [IF 5,536]

Ferrari A., Bertulli R.: At the crossroads of molecular biology, pathology and the clinic. *Expert Rev Anticancer Ther* 2012; 12: 725-728 [IF 2,652]

Ferrari S., Ruggeri P., Cefalo G., Tamburini A., Capanna R., Fagioli F., Comandone A., Bertulli R., Bisogno G., Palmerini E., Alberghini E., Parafioriti A., Linari A., Picci P., Bacci G.: Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1. *J Clin Oncol* 2012; 30: 2112-2118 [IF 18,372]

Fiore M., Colombo C., Locati P., Berselli M., Radaelli S., Morosi C., Casali P.G., Gronchi A.: Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol* 2012; 19: 511-518 [IF 4,166]

Gatta G., Ferrari A., Stiller C.A., Pastore G., Bisogno G., Trama A., Capocaccia R., Casali P.G., Gronchi A., Licitra L., The RARECARE Working Group: Embryonal cancers in Europe. *Eur J Cancer* 2012; 48: 1425-1433 [IF 5,536]

Grignani G., Palmerini E., Delie P., Asaftei S.D., D'Ambrosio L., Pignochino Y., Mercuri M., Picci P., Fagioli F., Casali P.G., Ferrari S., Aglietta M.: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. *Ann Oncol* 2012; 23: 508-516 [IF 6,425]

Gronchi A., Frustaci S., Mercuri M., Martin J., Lopez-Pousa A., Verderio P., Mariani L., Valagussa P., Miceli R., Stacchiotti S., Dei Tos P., De Paoli A., Longhi A., Poveda A., Quagliolo V., Comandone A., Casali P.G., Picci P.: Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma group and the Spanish Sarcoma Group. *J Clin Oncol* 2012; 30: 850-856 [IF 18,372]

Gronchi A., Miceli R., Colombo C., Stacchiotti S., Collini P., Mariani L., Sangalli C., Radaelli S., Sanfilippo G.R., Fiore M., Casali P.G.: Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. *Ann Oncol* 2012; 23: 1067-1073 [IF 6,425]

Italiano A., Cioffi A., Coco P., Maki R.G., Schoffski P., Rutkowski P., Le Cesne A., Duffaud F., Adenis A., Isambert N., Bompas E., Blay J.Y., Casali P.G., Keohan M.L., Toulmonde M., Antonescu C.R., Dwbiac-Rychter M., Coindre J.M., Bui B.: Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. *Ann Surg Oncol* 2012; 19: 1551-1559 [IF 4,166]

Le Cesne A., Cresta S., Maki R.G., Blay J.Y., Verweij J., Poveda A., Casali P.G., Balana C., Schöffski P., Grosso F., Lardelli P., Nieto A., Alfaro V., Demetri G.D.: A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. *Eur J Cancer* 2012; 48: 3036-3044 [IF 5,536]

Mallone S., De Vries E., Guzzo M., Midenia E., Verne J., Coebergh J.W., Marcos-Gragera R., Ardanaz E., Martinez R., Chirlaque M.D., Navarro C., Virgili G., Contiero P., Casali P.G., Gatta G., Gronchi A., Licitra L., Trama A., The RARECARE WG: Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. *Eur J Cancer* 2012; 48: 1167-1175 [IF 5,536]

Mandalà M., Grosso F., Vitalini C., Corradino I., Sanfilippo G.R., Colombini S., Clerici M., Labianca R., De Pascale A., Marsoni S.: Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies. *Br J Cancer* 2012; 107: 612-616 [IF 5,042]

Negri T., Brich S., Conca E., Bozzi F., Orsenigo M., Stacchiotti S., Alberghini M., Mauro V., Gronchi A., Dusio G.F., Pelosi G., Picci P., Casali P.G., Pierotti M.A., Pilotti S.: Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma. *Genes Chromosom Cancer* 2012; 51: 111-126 [IF 3,306]

Reichardt P., Blay J.Y., Boukovinas I., Brodowicz T., Broto J.M., Casali P.G., Decatris M., Eriksson M., Gelderblom H., Kosmidis P., Le Cesne A., Pousa A.L., Schlemmer M., Verweij J., Joensuu H.: Adjuvant therapy in primary GIST: state-of-the-art. *Ann Oncol* 2012; 23: 2776-2781 [IF 6,425]

Rinott R., Torresani M., Bertulli R., Goldsteen A., Casali P.G., Carmeli B., Slonim N.: Automatic Detection of Inconsistencies between Free Text and Coded Data in Sarcoma Discharge Letters. *Stud Health Technol Inform* 2012; 180: 661-666 [IF 0]

Rivoltini L., Marrari A., Castelli C., Villa S., Valdagni R.: Don't run before you can walk. (Letter) *Nat Rev Urol* 2012; 9: 602-603 [IF 4,415]

Siesling S., van der Zwan J.M., Izarzugaza I., Jaal J., Treasure T., Foschi R., Ricardi U., Groen H., Tavilla A., Ardanaz E., Casali P.G., Gatta G., Gronchi A., Licitra L., Trama A., Contiero P., on behalf of the RARECARE working group: Rare thoracic cancers, including peritoneum mesothelioma. *Eur J Cancer* 2012; 48: 949-960 [IF 5,536]

Stacchiotti S., Dagrada G.P., Morosi C., Negri T., Romanini A., Pilotti S., Gronchi A., Casali P.G.: Extraskelatal myxoid chondrosarcoma: tumor response to sunitinib. *Clin Sarcoma Res* 2012; 2: 22 [IF 0]

Stacchiotti S., Longhi A., Ferraresi V., Grignani G., Comandone A., Stupp R., Bertuzzi A., Tamborini E., Pilotti S., Messina A., Spreafico C., Gronchi A., Amore P., Vinaccia V., Casali P.G.: Phase II Study of Imatinib in Advanced Chordoma. *J Clin Oncol* 2012; 30: 914-920 [IF 18,372]

Stacchiotti S., Negri T., Libertini M., Palassini E., Marrari A., De Troia b., Gronchi A., Dei Tos A.P., Morosi C., Messina A., Pilotti S., Casali P.G.: Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012; 23: 3171-3179 [IF 6,425]

Stacchiotti S., Palassini E., Sanfilippo G.R., Vincenzi B., Arena M.G., Bochicchio A.M., De Rosa P., Nuzzo A., Turano S., Morosi C., Dei Tos A.P., Pilotti S., Casali P.G.: Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. *Ann Oncol* 2012; 23: 501-508 [IF 6,425]

Stacchiotti S., Verderio P., Messina A., Morosi C., Collini P., Llombart-Bosch A., Martin J., Comandone A., Cruz J., Ferraro A., Grignani G., Pizzamiglio S., Quagliolo V., Picci P., Frustaci S., Dei Tos A.P., Casali P.G., Gronchi A.: Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. *Cancer* 2012; 118: 5857-5866 [IF 4,771]

The ESMO European Sarcoma Network Working Group, Casali P.G., Ferrari A., Gronchi A., Stacchiotti S.: Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012; 23 (Suppl 7): 100-109 [IF 6,425]

The ESMO European Sarcoma Network Working Group, Casali P.G., Ferrari A., Gronchi A., Stacchiotti S.: Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012; 23 (Suppl. 7): 49-55 [IF 6,425]

The ESMO European Sarcoma Network Working Group, Casali P.G., Ferrari A., Gronchi A., Stacchiotti S.: Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2012; 23 (Suppl. 7): 92-99 [IF 6,425]

Trama A., Mallone S., Ferretti S., Meduri F., Capocaccia R., Gatta G., Berrino F., Casali P.G., Licitra L., and the RITA working Group: The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. *Tumori* 2012; 98: 550-558 [IF 0,606]

Trama A., Mallone S., Nicolai N., Necchi A., Schaapveld M., Gietema J., Znaor A., Ardanaz E., Berrino F., Casali P.G., Gatta G., Gronchi A., Licitra L., The RARECARE Working group: Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer* 2012; 48: 159-169 [IF 5,536]

van der Graaf W.T., Blay J.Y., Chawla S.P., Kim D.W., Bui-Nguyen B., Casali P.G., Schoffski P., Aglietta M., Staddon A.P., Beppu Y., Le Cesne A., Gelderblom H., Judson I.R., Araki N., Ouali M., Marreaud S., Hodge R., Dewji M.R., Coens C., Demetri G.D., Fletcher C.D., Dei Tos A.P., Hohenberger P., EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group: Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2012; 379: 1879-1886 [IF 38,278]

van der Zwan J.M., Mallone S., van Dijk B., Bielska-Lasota M., Otter R., Foschi R., Baudin R., Links T.P., Tagliabue G., Casali P.G., Gronchi A., Trama A., The RARECARE WG: Carcinoma of endocrine organs: Results of the RARECARE project. *Eur J Cancer* 2012; 48: 1923-1931 [IF 5,536]

Van Dijk B.A.C., Gatta G., Capocaccia R., Pierannunzio D., Strojan P., Licitra L., Casali P.G., Gronchi A., Ruzza M., Trama A., The RARECARE Working Group: Rare cancers of the head and neck area in Europe. *Eur J Cancer* 2012; 48: 783-796 [IF 5,536]

Vincenzi B., Santini D., Schiavon G., Frezza A.M., Silletta M., Crucitti P., Casali P.G., Dei Tos A.P., Rossi S., Rizzo S., Badalamenti G., Tomasino R.M., Russo A., Butrynski J.E., Tonini G.: PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy. *J Cell Physiol* 2012; 227: 1657-1662 [IF 3,874]

Visser O., Adolfsson J., Rossi S., Verne J., Gatta G., Maffezzini M., Franks K.N., Casali P.G., Gronchi A., Licitra L., Trama A.: Incidence and survival of rare urogenital cancers in Europe. *Eur J Cancer* 2012; 48: 456-464 [IF 5,536]

2011

Casali P.G., Sanfilippo G.R.: Uterine sarcomas: a multidisciplinary challenge. *Eur J Cancer* 2011; 47: Suppl. 3: 326-327

Casali P.G.: Medical oncology: the long-awaited prize of recognition. (Editorial) *Ann Oncol* 2011; 22: 1695-1697

Da Riva L., Bozzi F., Mondellini P., Miccichè F., Fumagalli E., Vaghi E., Tarantino E., Huber V., Gronchi A., Tamborini E., Pierotti M.A., Pilotti S., Bongarzone I.: Proteomic detection of a large amount of SCGF α in the stroma of GISTs after imatinib therapy. *J Transl Med* 2011; 9: 158

Dileo P., Pricl S., Tamborini E., Negri T., Stacchiotti S., Gronchi A., Posocco P., Laurini E., Coco P., Fumagalli E., Casali P.G., Pilotti S.: Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study. *Int J Cancer* 2011; 128: 983-990

Gatta G., van der Zwan J.M., Casali P.G., Siesling S., Dei Tos A.P., Kunkler I., Otter R., Licitra L., Mallone S., Tavilla A., Trama A., Capocaccia R., The RARECARE working group: Rare cancers are not so rare: The rare cancer burden in Europe. *Eur J Cancer* 2011; 47: 2493-2511 [IF 4,944]

Grignani G., Palmerini E., Stacchiotti S., Boggione A., Ferraresi V., Frustaci S., Comandone A., Casali P.G., Ferrari S., Aglietta M.: A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor- α or - β : An Italian Sarcoma Group study. *Cancer* 2011; 117: 826-831.

Gronchi A., Miceli R., Colombo C., Collini P., Stacchiotti S., Olmi P., Mariani L., Bertulli R., Fiore M., Casali P.G.: Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. *Ann Oncol* 2011; 22: 1675-1681.

Italiano A., Laurand A., Laroche A., Casali P.G., Sanfilippo G.R., Le Cesne A., Judson I., Blay J.Y., Ray-Coquard I., Nieto A., Tercere J.C., Jemeno J., Robert J., Pourquier P.: ERCC5/XPG, ERCC1, and

BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. *Cancer* 2011; 117: 3445-3456.

Joensuu H., De Braud F., Grignani G., De Pas T., Spitalieri G., Coco P., Spreafico C., Boselli S., Toffalori F., Bono P., Jalava T., Kappeler C., Aglietta M., Laurent D., Casali P.G.: Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study. *Br J Cancer* 2011; 104: 1686-1690.

2010

Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG, Gronchi A. Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution. *Ann Surg Oncol*. 2010 Jul 1. [Epub ahead of print]

Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21 Suppl 5:v98-102.

Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010 May;21 Suppl 5:v198-203.

Casali PG. Do rare cancers deserve specific strategies for cancer research? *Lancet Oncol*. 2010 Jun;11(6):506-7.

Casali PG, Sanfilippo R, D'Incalci M. Trabectedin therapy for sarcomas. *Curr Opin Oncol*. 2010 Jul;22(4):342-6.

Dileo P, Pricl S, Tamborini E, Negri T, Stacchiotti S, Gronchi A, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study. *Int J Cancer*. 2010 Apr 27.

Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG, Pilotti S. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. *Mol Cancer Ther*. 2010 May;9(5):1286-97.

Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaiene H, Le Péchoux C, Casali PG, Le Cesne A, Fiore M, Gronchi A. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. *Ann Surg Oncol*. 2010 Jun;17(6):1507-14.

Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, Gronchi A, Viridis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M, Allavena P. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. *Cancer Res*. 2010 Mar 15;70(6):2235-44. Epub 2010 Mar 9.

Ardoino I, Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG, Gronchi A. Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. *Cancer*. 2010 May 15;116(10):2429-36.

Tamborini E, Viridis E, Negri T, Orsenigo M, Brich S, Conca E, Gronchi A, Stacchiotti S, Manenti G, Casali PG, Pierotti MA, Pilotti S. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordoma. *Neuro Oncol* 2010 Feb 17. [Epub ahead of print]

Gronchi A, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M, Casali PG. Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution: The Local Control Directly Impacts Survival. *Ann Surg* 2010 Feb 2. [Epub ahead of print]

Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, Gronchi A, Casali PG. Tumor response to sunitinib malate observed in clear-cell sarcoma. *Ann Oncol* 2010 Jan 21. [Epub ahead of print]

Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, Gronchi A, Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. *Ann Surg Oncol*. 2010; 17: 211-9.

2009

Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). *Ann Surg Oncol*. 2009 Feb;16(2):463-72.

Bielack S, Carrle D, Casali PG; ESMO Guidelines Working Group. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2009 May;20 Suppl 4:137-9.

Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2009 May;20 Suppl 4:64-7.

Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2009 May;20 Suppl 4:132-6.

Conca E, Negri T, Gronchi A, Fumagalli E, Tamborini E, Pavan GM, Fermeglia M, Pierotti MA, Pricl S, Pilotti S. Activate and resist: L576P-KIT in GIST. *Mol Cancer Ther*. 2009 Sep;8(9):2491-5.

Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. *Clin Cancer Res*. 2009 Sep 15;15(18):5910-6.

Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG, Gronchi A. Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). *Eur J Surg Oncol*. 2009 Jul;35(7):739-45.

Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, Casali PG, Le Cesne A, Gronchi A, Bonvalot S. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol*. 2009 Sep;16(9):2587-93.

Forni C, Minuzzo M, Viridis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, Gronchi A, Aman P, Casali P, D'Incalci M, Pilotti S, Mantovani R. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. *Mol Cancer Ther*. 2009 Feb;8(2):449-57.

George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. *Eur J Cancer*. 2009 Jul;45(11):1959-68.

Gronchi A, Bonvalot S, Le Cesne A, Casali PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. *J Clin Oncol*. 2009 Apr 20;27(12):2106-7; author reply 2107-8.

Gronchi A, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Cesne AL, Hohenberger P, Blay JY. Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). *Eur J Cancer*. 2009 May;45(7):1103-6.

Gronchi A, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L, Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol*. 2009 Jan 1;27(1):24-30.

Grosso F, Sanfilippo R, Viridis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, Casali PG. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. *Ann Oncol*. 2009 Aug;20(8):1439-44.

Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. *J Clin Oncol*. 2009 Aug 20;27(24):3969-74.

Lessnick SL, Dei Tos AP, Sorensen PH, Dileo P, Baker LH, Ferrari S, Hall KS. Small round cell sarcomas. *Semin Oncol*. 2009 Aug;36(4):338-46.

Mertens F, Antonescu CR, Hohenberger P, Ladanyi M, Modena P, D'Incalci M, Casali PG, Aglietta M, Alvegård T. Translocation-related sarcomas. *Semin Oncol*. 2009 Aug;36(4):312-23.

Micheli A, Sanz N, Mwangi-Powell F, Coleman MP, Neal C, Ullrich A, Travado L, Santini LA, Grassi L, De Lorenzo F, Costa A, Dangou JM, Bisanti L, Seniori Costantini A, Abu-Rmeileh N, Kamal M, Federico M, Saracci R, Rennert G, Stefanini A, Cavalli F, Cazap E, Redmond K, O'Reilly S, Muti P, Casali P, Gatta G, Ferrari A, Koifman S, Bah E, Pastore G, Barr R, Lombardo C, Frazzinger C,

Ciampichini R, Baili P; ICCC-3 Session B Group. International collaborations in cancer control and the Third International Cancer Control Congress. *Tumori*. 2009 Sep-Oct;95(5):579-96.

Negri T, Bozzi F, Conca E, Brich S, Gronchi A, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S. Oncogenic and ligand-dependent activation of KIT/PDGFR α in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). *J Pathol*. 2009 Jan;217(1):103-12.

Paulussen M, Bielack S, Jürgens H, Casali PG; ESMO Guidelines Working Group. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2009 May;20 Suppl 4:140-2.

Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, Gronchi A, Casali PG. High-grade soft-tissue sarcomas: tumor response assessment--pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. *Radiology*. 2009 May;251(2):447-56.

Stacchiotti S, Marrari A, Tamborini E, Palassini E, Viridis E, Messina A, Crippa F, Morosi C, Gronchi A, Pilotti S, Casali PG. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol*. 2009 Nov;20(11):1886-94.

Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, Crippa F, Morosi C, Gronchi A, Pierotti MA, Casali PG, Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma. *Clin Cancer Res*. 2009 Feb 1;15(3):1096-104.